Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04414124 · ClinicalTrials.gov registry record · NA
A Clinical Study to Assess the Natural History of COVID-19 and Effects of KB109 and Supportive Self-care in Outpatients With Mild-to-moderate COVID-19
A NA study, sponsored by Kaleido Biosciences.
- Completed
- Registry status
- NA
- Development phase
- 350
- Enrollment target
NCT04414124: Completed NA study, sponsored by Kaleido Biosciences.
NCT04414124 is a NA study that has completed, run by Kaleido Biosciences. The registered enrollment target is 350 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (75% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04414124, a NA study, has completed, sponsored by Kaleido Biosciences.
- COMPLETED
- Registry status
- NA
- Development phase
- 350 participants
- Enrollment target
Study Summary
This randomized, open-label, prospective, parallel-group controlled clinical study that aims to explore the natural history of COVID-19 illness and the safety of KB109, a novel glycan, plus SSC versus SSC alone and measures of health in outpatients with mild-to-moderate COVID-19.
Interventions
- OTHER KB109 + Self Supportive Care (SSC)
- OTHER Self Supportive Care (SSC) Alone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2020-08-02 |
| Est. Completion | 2021-02-02 |
| Phase | NA |
What the finished NCT04414124 record still lists
NCT04414124 is an interventional study that assigns participants to a tested intervention. The registered 350 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (75% lower).
The record links to 0 conditions, and to 2 interventions - of which KB109 + Self Supportive Care (SSC) is the first listed.
NCT04414124 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04414124 about?
NCT04414124 is a clinical study titled "A Clinical Study to Assess the Natural History of COVID-19 and Effects of KB109 and Supportive Self-care in Outpatients With Mild-to-moderate COVID-19". This randomized, open-label, prospective, parallel-group controlled clinical study that aims to explore the natural history of COVID-19 illness and the safety of KB109, a novel glycan, plus SSC versus SSC alone and measures of health in outpatients with mild-to-moderate COVID-19.
What is the current status of trial NCT04414124?
This trial is currently completed. It is a NA study. The enrollment target is 350 participants. The study started on 2020-08-02. Estimated completion is 2021-02-02.
What interventions are being tested in trial NCT04414124?
The interventions under investigation include: KB109 + Self Supportive Care (SSC) (OTHER), Self Supportive Care (SSC) Alone (OTHER).
Who is sponsoring clinical trial NCT04414124?
This trial is sponsored by Kaleido Biosciences, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04414124's enrollment target sits among peer trials
350 292nd of 2000 higher than 1,699 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00900575 · 350 participants · NA
Cervical Cancer Detection Using Optical Spectroscopy
- NCT01627821 · 350 participants · NA
Evaluation of the Jarvik 2000 Left Ventricular Assist System With Post-Auricular Connector--Destination Therapy Study
- NCT02357654 · 350 participants · Phase 4
GnRH for Luteal Support in IVF/ICSI/FET Cycles
- NCT03997370 · 350 participants · Phase 1
Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI